Key result
CEFIP drives cardiomyocyte hypertrophy by enhancing calcineurin/NFAT signaling.
The novel z-disc protein CEFIP modulates calcineurin/NFAT signaling to regulate cardiomyocyte hypertrophy, offering a potential new mechanism in the pathogenesis of cardiomyopathy.
Does not support clinical translation yet; leaves open CEFIP as a hypertrophic target requiring human validation.
rotein (CEFIP), which exhibited a heart- and skeletal muscle-specific expression profile. Importantly, CEFIP was located at the z-disc and was up-regulated in several models of cardiomyopathy. We also found that CEFIP overexpression induced the fetal gene program and cardiomyocyte hypertrophy. Yeast two-hybrid screens revealed that CEFIP interacts with the calcineurin-binding protein four and a half LIM domains 2 (FHL2). Because FHL2 binds calcineurin, a phosphatase controlling hypertrophic signaling, we examined the effects of CEFIP on the calcineurin/nuclear factor of activated T-cell (NFAT) pathway. These experiments revealed that CEFIP overexpression further enhances calcineurin-dependent hypertrophic signal transduction, and its knockdown repressed hypertrophy and calcineurin/NFAT activity. In summary, we report on a previously uncharacterized protein CEFIP that modulates calcineurin/NFAT signaling in cardiomyocytes, a finding with possible implications for the pathogenesis of cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Dierck et al. (2017) studied Cardiomyopathy. CEFIP overexpression and knockdown was evaluated on Cardiomyocyte hypertrophy and calcineurin/NFAT signaling. CEFIP overexpression enhanced calcineurin-dependent hypertrophic signal transduction, while its knockdown repressed hypertrophy and calcineurin/NFAT activity in cardiomyocytes.
Synapse has enriched 5 related papers. Consider them for comparative context: